Shugan Dingtong Decoction in the Treatment of Fibromyalgia
Key facts
- Who runs it
- China-Japan Friendship Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 72 people enrolled
- Started
- 1 Sept 2022
- Ended
- 18 Oct 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Shugan Dingtong decoction
- Duloxetine Hydrochloride
- Record updated
- 19 November 2024
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- patients aged 18-70 years old
- patients who meet the diagnostic criteria of American College of Rheumatology in 2016
- patients who meet the diagnostic criteria of Syndrome of stagnation of liver qi
- pain scores between3 and 7 on visual analogue scale
- patients sign the informed consent forms
Who cannot take part
- patients are participation in any other clinical trials or receive other drugs for the treatment of fibromyalgia
- patients with serious primary diseases of respiratory, digestive, urinary, cardiovascular and immune system
- patients with mental and psychological disorders including cognitive im-pairment, severe depression, somatoform disorders
- patients with secondary fibromyalgia resulted from osteoarthritis, rheumatoid arthritis, trauma, hypothyroidism, malignant tumor
- patients who are allergic to the drugs used in this study
- pregnant and lactating women
- patients with severe pain resulted from diabetic and postherpetic neuralgia
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Fibromyalgia (FM) is a syndrome characterized by chronic and widespread musculoskeletal pain, fatigue sleep disturbances and cognitive and somatic symptoms. It is commonly conjectured that central sensitization is physiological hallmark of FM. Therefore, centrally acting medications including antidepressants and anticonvulsants are used to treat FM via downregulating dorsal horn sensitization and systemic hyperexcitability.However, those drugs are limited in clinical practice resulting from dose-limiting adverse effects and incomplete drug efficacy.Shugan Dingtong decoction(SGDTD) is a Chinese herbal formula and has been used for treatment of FM in clinical practice many years. However, few research can provide high-quality evidence on the efficacy and safety of SGDTD for the treatment of FM. Therefore, a parallel-group randomized controlled trial was designed to evaluate the efficacy and safety of SGDTD on FM.
The 2 groups in the trial
- Shugan Dingtong decoctionTreatment being tested
Patients will accept Shugan Dingtong decoction 150ml (twice, per day) for 12 weeks.
- duloxetine hydrochlorideExisting treatment, for comparison
Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Efficacy and Safety of the Shugan Dingtong Decoction in the Treatment of Fibromyalgia
- Publications
- Osteoarthritis and Degree of Fatigue are Associated with Pain Levels in Patients with Fibromyalgia Syndrome: A Cross-Sectional Study of 394 Patients.International journal of general medicine, 2025
- Record updated
- 19 November 2024